Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131412) titled 'Fuzheng Huayu Tablets plus Anti-HBV Therapy for Liver Fibrosis or Early Cirrhosis in Patients with Chronic Hepatitis B and Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Trial' on Sept. 2.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Third Affiliated Hospital Sun Yat-sen University
Condition:
CHB complicated with NAFLD( (Pattern of Blood Stasis Obstructing the Collaterals with Liver-Kidney Deficiency)
Intervention:
control group:Standard antiviral therapy plus the placebo for Fuzheng Huayu Tablets
Recruitment Status: Recruiting
Phase: N...